Par Drugs and Chemicals Limited (NSE:PAR)
India · Delayed Price · Currency is INR 89.31
+0.22 (0.25%)
Jun 1, 2026, 3:08 PM IST
Par Drugs and Chemicals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,037 | 1,010 | 956.4 | 957.49 | 750.74 |
Other Revenue | 40.01 | - | - | - | - |
| 1,077 | 1,010 | 956.4 | 957.49 | 750.74 | |
Revenue Growth (YoY) | 6.62% | 5.58% | -0.11% | 27.54% | 23.58% |
Cost of Revenue | 433.61 | 391.87 | 346.53 | 409.83 | 293.18 |
Gross Profit | 642.95 | 617.86 | 609.88 | 547.65 | 457.57 |
Selling, General & Admin | 61.2 | 58.52 | 54.99 | 48.88 | 41.01 |
Other Operating Expenses | 370.43 | 364.24 | 326.71 | 316.7 | 254.01 |
Operating Expenses | 468.66 | 459.23 | 416.06 | 397.91 | 327.83 |
Operating Income | 174.29 | 158.64 | 193.81 | 149.74 | 129.74 |
Interest Expense | -1.27 | - | - | -0.02 | -3.77 |
Interest & Investment Income | - | 10.81 | 2.32 | 0.72 | 1.84 |
Other Non Operating Income (Expenses) | - | -0.82 | -1.07 | -1.31 | -0.78 |
EBT Excluding Unusual Items | 173.02 | 168.62 | 195.07 | 149.13 | 127.03 |
Gain (Loss) on Sale of Investments | - | 10.61 | 0.02 | - | - |
Gain (Loss) on Sale of Assets | - | - | 0.08 | 1.43 | - |
Pretax Income | 173.02 | 179.23 | 195.17 | 150.79 | 127.03 |
Income Tax Expense | 41.93 | 45.65 | 50.16 | 37.45 | 34.9 |
Net Income | 131.09 | 133.58 | 145.01 | 113.34 | 92.13 |
Net Income to Common | 131.09 | 133.58 | 145.01 | 113.34 | 92.13 |
Net Income Growth | -1.87% | -7.88% | 27.94% | 23.02% | -20.65% |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 12 |
Shares Change (YoY) | 0.03% | - | - | - | - |
EPS (Basic) | 10.65 | 10.86 | 11.78 | 9.21 | 7.49 |
EPS (Diluted) | 10.65 | 10.86 | 11.78 | 9.21 | 7.49 |
EPS Growth | -1.90% | -7.84% | 27.90% | 23.00% | -20.64% |
Free Cash Flow | 144.71 | 149.34 | 141.69 | 57.43 | 44.13 |
Free Cash Flow Per Share | 11.76 | 12.14 | 11.52 | 4.67 | 3.59 |
Dividend Per Share | - | - | - | - | 1.250 |
Gross Margin | 59.72% | 61.19% | 63.77% | 57.20% | 60.95% |
Operating Margin | 16.19% | 15.71% | 20.27% | 15.64% | 17.28% |
Profit Margin | 12.18% | 13.23% | 15.16% | 11.84% | 12.27% |
Free Cash Flow Margin | 13.44% | 14.79% | 14.81% | 6.00% | 5.88% |
EBITDA | 211.32 | 195.1 | 228.17 | 182.07 | 162.55 |
EBITDA Margin | 19.63% | 19.32% | 23.86% | 19.02% | 21.65% |
D&A For EBITDA | 37.03 | 36.47 | 34.36 | 32.33 | 32.81 |
EBIT | 174.29 | 158.64 | 193.81 | 149.74 | 129.74 |
EBIT Margin | 16.19% | 15.71% | 20.27% | 15.64% | 17.28% |
Effective Tax Rate | 24.23% | 25.47% | 25.70% | 24.84% | 27.47% |
Revenue as Reported | 1,077 | 1,031 | 958.83 | 959.87 | 752.58 |